Akebia Therapeutics, Inc. Stock News

CAMBRIDGE, Mass. , Nov. 25, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a Fireside Discussion at the 36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3 rd at 10:30 AM EST.

Akebia Therapeutics, Inc.'s stock has surged nearly 35% after positive updates on its Vafseo (vadadustat) and promising third-quarter results, despite macroeconomic challenges. The company is expanding its market through partnerships and trials, addressing unmet needs in anemia treatment for CKD patients, and exploring label expansion. Risks include potential competition post-2025 due to patent...

Akebia continues to publish important results of FO2CUS trial to further physicians' understanding of Vafseo® (vadadustat)  CAMBRIDGE, Mass. , Nov. 14, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the American Journal of Kidney Disease has published the ...

CAMBRIDGE, Mass. , Nov. 12, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies London Healthcare Conference on Thursday, November 21 at 1:00 PM GMT.

Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, Investor Relations John Butler - Chief Executive Officer Nick Grund - Chief Commercial Officer Erik Ostrowski - Chief Financial and Business Officer Conference Call Participants Allison Bratzel - Piper Sandler Ed Arce - H.C. Wainwright J...

Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025 Over 300,000 patients, representing approximately 60% of dialysis patient lives in the U.S., now covered under dialysis provider contracts for Vafseo Vafseo granted TDAPA reimbursement and issued a Level II Healthcare Common Procedure Coding System code Akebia to Host Conference Call at 8:00 a.m. ET on November ...

CAMBRIDGE, Mass. , Nov. 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 20,000 shares of Akebia's common stock on October 31, 2024.

Akebia to Host Conference Call on November 7, 2024, at 8:00 a.m. EST CAMBRIDGE, Mass.